Clearstead Advisors’s Black Diamond Therapeutics BDTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BDTX
Clearstead Advisors's BDTX Position: Q3 2026 in Review
Clearstead Advisors opened a new position in Black Diamond Therapeutics (BDTX) in Q3 2026: 5 shares worth $10. The stake represents ﹤0.01% of the portfolio and ranks #3473 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in BDTX as recently as Q3 2022.
Clearstead Advisors first reported a position in BDTX in Q2 2021 and has held it in 7 quarters since. The position peaked at $1K in Q3 2021. 110 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.
- Clearstead Advisors held 5 shares of Black Diamond Therapeutics worth $10 as of Q3 2026.
- Black Diamond Therapeutics was a new Clearstead Advisors position in Q3 2026.
- Black Diamond Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #3473 holding.
- Clearstead Advisors first reported a position in Black Diamond Therapeutics in Q2 2021 and has held it in 7 quarters since.
- Clearstead Advisors's Black Diamond Therapeutics position peaked at $1K in Q3 2021.
- 110 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.
Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.